Last reviewed · How we verify
A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®
A pilot study to evaluate the impact of Lotemax® Gel (loteprednol etabonate ophthalmic gel 0.5%) on the initiation of Restasis® (cyclosporine ophthalmic emulsion 0.05%) therapy in subjects with dry eye.
Details
| Lead sponsor | Edward Holland, MD |
|---|---|
| Phase | Phase 4 |
| Status | WITHDRAWN |
| Start date | 2014-01 |
| Completion | 2016-06 |
Conditions
- Dry Eye Disease
Interventions
- Loteprednol etabonate
- Artificial Tears
- Restasis
Primary outcomes
- Fluorescein corneal staining scores — 60 Days
Countries
United States